|
Age, n (%)
|
|
< 65 years
|
47 (56.0)
|
43 (54.4)
|
|
≥ 65 years
|
37 (44.0)
|
36 (45.6)
|
|
Sex, n (%)
|
|
Male
|
47 (56.0)
|
45 (57.0)
|
|
Female
|
37 (44.0)
|
34 (43.0)
|
|
Race, n (%)
|
|
White
|
69 (82.1)
|
66 (83.5)
|
|
Nonwhite
|
15 (17.9)
|
13 (16.5)
|
|
Body mass index, n (%)
|
n = 83
|
n = 78
|
|
< 18.5 kg/m2
|
3 (3.6)
|
4 (5.1)
|
|
≥ 18.5 to < 25 kg/m2
|
22 (26.5)
|
21 (26.9)
|
|
≥ 25 to < 30 kg/m2
|
20 (24.1)
|
22 (28.2)
|
|
≥ 30 kg/m2
|
38 (45.8)
|
31 (39.7)
|
|
Geographic region, n (%)
|
|
Australia/New Zealand
|
17 (20.2)
|
11 (13.9)
|
|
Europe
|
10 (11.9)
|
9 (11.4)
|
|
USA/Canada
|
57 (67.9)
|
59 (74.7)
|
|
Albumin, n (%)
|
n = 78
|
n = 76
|
|
< 2.5 g/dL
|
56 (71.8)
|
47 (61.8)
|
|
≥ 2.5 g/dL
|
22 (28.2)
|
29 (38.2)
|
|
Cause of shock, n (%)
|
|
Sepsis
|
68 (81.0)
|
59 (74.7)
|
|
Likely sepsis
|
8 (9.5)
|
12 (15.2)
|
|
Vasoplegia
|
3 (3.6)
|
7 (8.9)
|
|
Other
|
5 (6.0)
|
1 (1.3)
|
|
Baseline MAP,* n (%)
| | |
|
< 65 mmHg
|
37 (44.0)
|
15 (19.0)
|
|
≥ 65 mmHg
|
47 (56.0)
|
64 (81.0)
|
|
Baseline APACHE II score, n (%)
|
|
≤ 30
|
54 (64.3)
|
51 (64.6)
|
|
31–40
|
29 (34.5)
|
21 (26.6)
|
|
≥ 41
|
1 (1.2)
|
7 (8.9)
|
|
Norepinephrine-equivalent dose 6 h before randomization, mean, µg/kg/min (SD)
|
0.52 (0.301)
|
0.45 (0.377)
|
|
Baseline norepinephrine-equivalent dose,* n (%)
|
|
< 0.5 µg/kg/min
|
50 (59.5)
|
67 (84.8)
|
|
≥ 0.5 µg/kg/min
|
34 (40.5)
|
12 (15.2)
|
|
Baseline angiotensin I,* n (%)
|
n = 74
|
n = 71
|
|
Mean (SD)
|
678.9 (810.8)
|
618.0 (1332.5)
|
|
Median (range)
|
346.0 (10.5–3730.0)
|
164 (10.5–9180.0)
|
|
< 72.3 pg/mL
|
12 (16.2)
|
24 (33.8)
|
|
72.3 to < 253 pg/mL
|
14 (18.9)
|
19 (26.8)
|
|
253 to < 676 pg/mL
|
25 (33.8)
|
14 (19.7)
|
|
≥ 676 pg/mL
|
23 (31.1)
|
14 (19.7)
|
|
Baseline angiotensin II,* n (%)
|
n = 74
|
n = 70
|
|
Mean (SD)
|
420.8 (680.3)
|
128.3 (199.1)
|
|
Median (range)
|
157.5 (10.5–3340.0)
|
61.3 (10.5–1090.0)
|
|
< 23.85 pg/mL
|
14 (18.9)
|
21 (30.0)
|
|
23.85 to < 83.75 pg/mL
|
11 (14.9)
|
21 (30.0)
|
|
83.75 to < 299.5 pg/mL
|
25 (33.8)
|
21 (30.0)
|
|
≥ 299.5 pg/mL
|
24 (32.4)
|
7 (10.0)
|
|
Exposure to angiotensin-converting enzyme inhibitors
|
7 (8.3)
|
8 (10.1)
|
|
Exposure to angiotensin II receptor blockers
|
9 (10.7)
|
2 (2.5)
|
|
Radiographic finding of ARDS
|
23 (27.4)
|
17 (21.5)
|
|
Cardiac index (L/min/m2)
|
n = 36
|
n = 33
|
|
Mean (SD)
|
3.5 (1.07)
|
3.1 (0.73)
|
|
Median (range)
|
3.1 (2.3–6.4)
|
3.0 (2.1–5.4)
|
|
ScvO2 (%)
|
n = 59
|
n = 61
|
|
Mean (SD)
|
78.2 (8.14)
|
77 (9.64)
|
|
Median (range)
|
79.0 (53–99)
|
75.9 (45–99)
|
|
Central venous pressure (mmHg)
|
n = 64
|
n = 62
|
|
Mean (SD)
|
14.3 (5.8)
|
13.2 (4.1)
|
|
Median (range)
|
13.0 (5–35)
|
12.0 (6–29)
|
|
SOFA score
|
|
Mean (SD)
|
12.0 (2.8)
|
11.5 (2.8)
|
|
Median (range)
|
12.0 (5–18)
|
12.0 (5–18)
|
